"I've always believed in doing what's best for Indy, not what's politically convenient. This map fails that test," former ...

Levi Garraway, Roche's chief medical officer and head of global product development. Roche has built the evidence for its oral BTK inhibitor fenebrutinib in multiple sclerosis (MS) with two phase 3 ...

Roche Holding's fair value estimate has seen a modest increase, with the latest target rising from CHF 298.64 to CHF 304.50. This change follows analyst updates that reflect a balance of positive ...

Roche shares rose after the Swiss pharmaceutical company said an experimental pill for breast cancer showed positive results in a large late-stage trial. The drugmaker said Tuesday that the trial ...

FRANKFURT, Nov 18 (Reuters) - Roche's <ROG.S, opens new tab experimental oral drug giredestrant has been shown to cut the risk of recurrence of a common form of breast cancer after surgery, boosting ...

Roche has reported another phase 3 win for its oral selective estrogen receptor degrader (SERD). Success at a planned interim analysis positions giredestrant for use in the adjuvant setting, setting ...

Roche reported positive Phase III results on trials of its new multiple sclerosis (MS) drug today. Fenebrutinib appears effective at treating both relapsing multiple sclerosis and primary progressive ...

Roche said its fenebrutinib drug candidate met primary goals in two late-stage trials for multiple sclerosis, reducing attacks or delaying disability progression in two different forms of the disease.

Roche has reported wins for its BTK inhibitor fenebrutinib in a pair of phase 3 studies across two multiple sclerosis (MS) populations. One victory was based on the finding that the candidate was ...